🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

242 results for “ANI” Clear

  1. Ozanimod, Ozanimod, Ozanimod

    Bristol-Myers Squibb / Pfizer EEIG

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  2. PANITUMUMAB, CAPECITABINE, CAPECITABINE, DISODIUM LEVOFOLINATE, CALCIUM LEVOFOLINATE, FLUOROURACIL, NIVOLUMAB, TEMOZOLOMIDE, FOLINIC ACID, TRASTUZUMAB, TEMOZOLOMIDE, PERTUZUMAB, TEMOZOLOMIDE, OXALIPLATIN, IPILIMUMAB, IRINOTECAN

    Fondazione Telethon ETS

    Colon cancer

    phase 3 small molecule active

    1 trial

  3. PEMBROLIZUMAB , IMFINZI 50 mg/mL concentrate for solution for infusion., JZP598, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Jazz Pharmaceuticals Ireland Limited

    BTC - Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  4. Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung

    Incyte Biosciences Distribution B.V.

    Metastatic nonsquamous or squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  5. Placebo matching Ozanimod hard-gelatin capsules, Ozanimod, Ozanimod

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  6. Pretomanid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Pulmonary

    phase 3 small molecule completed

    2 trials

  7. Prostavue

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  8. Ranibizumab

    Regeneron UK Limited

    Macular Degeneration

    phase 3 small molecule completed

    2 trials

  9. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg

    Sunshine Biopharma

    Acute Gout

    phase 3 small molecule active

    2 trials

  10. Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  11. Remifentanil

    China SXT Pharmaceuticals

    Analgesia

    phase 3 small molecule active

    1 trial

  12. Remimazolam Besylate

    First Tracks Biotherapeutics

    Critical Illness; Mechanical Ventilation; Shock

    phase 3 small molecule active

    1 trial

  13. Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

  14. Sufentanil 30 MCG Sublingual Tablet

    United Therapeutics Europe Ltd

    Traumatic Injury

    phase 3 small molecule completed

    1 trial

  15. Sufentanil Mylan 50 microgrammes/ml solution injectable, MORPHINE HYDROCHLORIDE, CHLORURE DE SODIUM 0,9 % LAVOISIER, solution pour perfusion

    Pari Pharma GmbH

    vaso-occlusive crisis due to sickle cell disease

    phase 3 small molecule active

    1 trial

  16. Sutent 12.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PAZOPANIB , Sutent 25 mg hard capsules

    Incyte Biosciences Distribution B.V.

    Locally advanced/metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  17. TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment

    Almirall

    Actinic Keratosis on the Face or Scalp

    phase 3 small molecule active

    1 trial

  18. Tamiflu 75 mg hard capsules, DOLIPRANE 1000 mg, poudre pour solution buvable en sachet-dose

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  19. Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial

  20. Transcranial Magnetic stimulation

    CNS Pharmaceuticals

    Gambling Disorder

    phase 3 other active

    1 trial

  21. VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, AMPHOTERICINE B, LIPOSOME, FLUCONAZOLE, FLUCONAZOLE, AMPHOTERICINE B, LIPOSOME, VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, MICAFUNGIN, MICAFUNGIN

    Pari Pharma GmbH

    Uncomplicated candidemia

    phase 3 small molecule active

    1 trial

  22. XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial

  23. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  24. Yutiq 0.18 MG Drug Implant

    ANI PHARMACEUTICALS INC

    Uveitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources